Navigation Links
Accurate Identification of Tumor Origin Using MicroRNAs is Published by Rosetta Genomics' Scientists and Collaborators in Nature Biotechnology
Date:3/24/2008

aterially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics and therapeutic tools, which is unproven and may never lead to marketable products or services; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its candidate tools, products and services, all of which are in early stages of development; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2006 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Contact: Media

Rachel Spielman

T: +1-212-583-2714

E:

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
2. ABCs Private Practice Inaccurately Portrays Serious Womens Health Condition
3. Mobidiag Releases First Microarray Based Rapid Test for Herpesvirus Identification
4. Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
5. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
6. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
7. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
8. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics Tissue of Origin Test Designed to Aid in Determination of a Tumors Origin
9. On the road to a new cancer therapy -- starving the tumor
10. Elekta Announces Elekta Infinity - a New System for Faster and More Precise Treatment of Cancer Tumors
11. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Biotech Ltd. (Nasdaq: SVA ), a leading provider ... announced that it will release its unaudited financial results for ... on Thursday, August 14, 2014 EDT. The Company will host ... August 15, 2014, at 8:00 a.m. EDT (Friday, August 15, ... Company,s financial results and provide an update on recent corporate ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, announced today that ... presentation to investors on Tuesday, July 29, 2014, ... presentation will include an overview of Asterias, business ... webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 ...
(Date:7/24/2014)... Professor of Engineering at the University of Delaware, ... problems in energy engineering, environmental sustainability and electronics. ... porous rock with a well-defined, crystalline structure. At ... precisely decided that zeolites can separate molecules with ... angstrom (one-tenth of a nanometer), making them useful ...
(Date:7/24/2014)... 24, 2014 SRI International has been awarded ... Institute of Allergy and Infectious Diseases (NIAID), part of ... of potential therapies for HIV infection and AIDS. The ... and AIDS and the complications and opportunistic infections associated ... sexual transmission of HIV. According to ...
Breaking Biology Technology:Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4University of Delaware researcher describes new approach for creating organic zeolites 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
... CONTINUE TO MANAGE ALS EAP IN ITALY AND ALL ... RESPONSIBILITY FOR REST OF WORLD , RICHMOND, Va., ... ), a biopharmaceutical company, today announced the signing of ... in the management of medicines on a named patient ...
... TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) ... the Southern District of New York dismissed proceedings filed ... ("Axonyx") against Axonyx and several of Axonyx,s former directors ... plaintiffs alleged that the defendants made misleading statements related ...
... Inverness Medical Innovations, Inc. (NYSE: IMA ), a ... health at home through the merger of rapid diagnostics and ... on its Series B Convertible Perpetual Preferred Stock (NYSE: IMA-PB). ... stock in an amount per share equal to the quotient ...
Cached Biology Technology:Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM) 2Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM) 3Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM) 4Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed 2
(Date:7/25/2014)... scientists from 25 countries and 35 states will ... the Genetics Society of America (GSA) next week ... conference will feature close to 500 presentations (including ... including gene expression and regulation, functional genomics, chemical ... and a variety of diseases. , Of ...
(Date:7/25/2014)... at the University of Adelaide has opened the way for ... powdery mildew. , In Australia, annual barley production is second ... mildew is one of the most important diseases of barley. ... discovered the composition of special growths on the cell walls ... into the leaf. , The research, by the ARC Centre ...
(Date:7/25/2014)... After development of diffusion tensor tractography (DTT), which ... reconstruction and estimation for three motor tracts, such ... the corticoreticular pathway became possible. The corticospinal tract ... for motor function in the human brain. Several ... tract by transtentorial herniation. In addition, some studies ...
Breaking Biology News(10 mins):Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2New hope for powdery mildew resistant barley 2
... Mich.---In cells, as in cities, disposing of garbage and ... service. In both city and cell, health problems can ... research by University of Michigan cell biologist Haoxing Xu ... garbage dump and recycling center, the lysosome, functions. These ...
... 14, 2010 The Institute for Clinical & Translational ... five years from the National Institutes of Health to ... for patients. UCI is the first medical research ... to receive the competitive Clinical & Translational Science ...
... (July 13, 2010) -- The 52nd meeting of ... convenes from July18 - 22, 2010 in Philadelphia, ... medical physics, a broadly-based scientific and professional discipline ... biology. Its membership includes medical physicists who specialize ...
Cached Biology News:Opening the gate to the cell's recycling center 2UCI receives prestigious federal research award to hasten medical advances 2Nanotech medicine, tumor tracking, new technologies and more 2Nanotech medicine, tumor tracking, new technologies and more 3Nanotech medicine, tumor tracking, new technologies and more 4Nanotech medicine, tumor tracking, new technologies and more 5Nanotech medicine, tumor tracking, new technologies and more 6Nanotech medicine, tumor tracking, new technologies and more 7Nanotech medicine, tumor tracking, new technologies and more 8Nanotech medicine, tumor tracking, new technologies and more 9Nanotech medicine, tumor tracking, new technologies and more 10Nanotech medicine, tumor tracking, new technologies and more 11Nanotech medicine, tumor tracking, new technologies and more 12Nanotech medicine, tumor tracking, new technologies and more 13Nanotech medicine, tumor tracking, new technologies and more 14Nanotech medicine, tumor tracking, new technologies and more 15Nanotech medicine, tumor tracking, new technologies and more 16Nanotech medicine, tumor tracking, new technologies and more 17
Anti-human C5/C5b, Clone 568, Monoclonal Antibody...
Gentamicin sulfate, 5g...
... [EP282Y] to Asparagine synthetase ( ... applications). Antigen: ... residues in the C-terminus of ... Entrez GeneID: 440 ...
Anti-gamma Glutamyl Transferase (gammaGT) Host: mouse monoclonal Species Reactivity: human Applications: WB, IP, FC Storage: 4C...
Biology Products: